Skip to main content
. Author manuscript; available in PMC: 2011 Feb 27.
Published in final edited form as: Life Sci. 2009 Dec 1;86(9-10):289–299. doi: 10.1016/j.lfs.2009.11.020

Figure 2.

Figure 2

Figure 2

Relative risk for cardiovascular outcomes in patients with chronic kidney disease. (A) ACEIs or ARBs Versus Placebo; (B) ACEIs or ARBs Versus Non-RAAS Antihypertensives. *P<0.05, †P=0.05. ACEI = angiotensin-converting enzyme inhibitor; ACM = all-cause mortality; ARB = angiotensin receptor blocker; CHF = congestive heart failure; CKD = chronic kidney disease; CVA = cerebrovascular accident; CVM = cardiovascular mortality; MCE = major cardiovascular event (eg, MI, CVA, coronary revascularization, unstable angina); MI = myocardial infarction; RAAS = renin-angiotensin-aldosterone system. Adapted from Balamuthusamy et al. (Balamuthusamy et al. 2008)

[Note: for black & white reproduction/printing only]